Emmanuel Antonarakis

Professor

20022019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Emmanuel Antonarakis is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 16 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
Castration Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Androgen Receptors Medicine & Life Sciences
Androgens Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Prostate-Specific Antigen Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer

Taplin, M. E., Antonarakis, E. S., Ferrante, K. J., Horgan, K., Blumenstein, B., Saad, F., Luo, J. & de Bono, J. S., Dec 2019, In : European Urology. 76, 6, p. 843-851 9 p.

Research output: Contribution to journalArticle

Castration
Androgen Receptors
Prostatic Neoplasms
Circulating Neoplastic Cells
MDV 3100

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer

Antonarakis, E., Jan 1 2019, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Prostatic Neoplasms

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

Kapoor, R., Deek, M. P., McIntyre, R., Raman, N., Kummerlowe, M., Chen, I., Gaver, M., Wang, H., Denmeade, S., Lotan, T., Paller, C., Markowski, M., Carducci, M., Eisenberger, M., Beer, T. M., Song, D. Y., Deweese, T. L., Hearn, J. W., Greco, S., Deville, C. & 7 others, Desai, N. B., Heath, E. I., Liauw, S., Spratt, D. E., Hung, A. Y., Antonarakis, E. S. & Tran, P. T., Jun 13 2019, In : BMC cancer. 19, 1, 572.

Research output: Contribution to journalArticle

Open Access
Salvage Therapy
Prostatectomy
Double-Blind Method
Prostatic Neoplasms
Radiotherapy

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer

McHugh, D., Eisenberger, M., Heath, E. I., Bruce, J., Danila, D. C., Rathkopf, D. E., Feldman, J., Slovin, S. F., Anand, B., Chu, R., Lackey, J., Reyno, L., Antonarakis, E. & Morris, M. J., Jan 1 2019, In : Investigational New Drugs.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Maximum Tolerated Dose
Antibodies
Fatigue

A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer

Paller, C., Piana, D., Eshleman, J., Riel, S., Denmeade, S. R., Isaacsson Velho, P., Rowe, S., Pomper, M. G., Antonarakis, E., Luo, J. & Eisenberger, M., Jan 1 2019, In : Prostate. 79, 14, p. 1597-1603 7 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Circulating Neoplastic Cells
Therapeutics
Castration
Prostate-Specific Antigen